Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study

N Rasgon, K W Lin, J Lin, E Epel, E Blackburn, N Rasgon, K W Lin, J Lin, E Epel, E Blackburn

Abstract

We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with unremitted depression. In addition we examined correlation between LTL and the insulin resistance (IR) status in these subjects. Forty-two medically stable men and women ages 23-71 with non-remitted depression participated in double-blind placebo-controlled add-on of Pioglitazone to treatment-as-usual. Oral glucose tolerance tests were administered at baseline and at 12 weeks. Diagnostic evaluation of psychiatric disorders was performed at baseline and mood severity was followed weekly throughout the duration of the trial. At baseline, no differences in LTL were detected by depression severity, duration or chronicity. LTL was also not significantly different between insulin-resistant and insulin-sensitive subjects at baseline. Subjects with longer telomeres exhibited greater declines in depression severity in the active arm, but not in a placebo arm, P=0.005, r=-0.63, 95% confidence interval (95% CI)=(-0.84,-0.21). In addition, LTL predicted improvement in insulin sensitivity in the group overall and did not differ between intervention arms, P=0.036, r=-0.44, 95% CI=(-0.74,0.02) for the active arm, and P=0.026, r=-0.50, 95% CI=(-0.78,-0.03) for the placebo arm. LTL may emerge as a viable predictor of antidepressant response. An association between insulin sensitization and LTL regardless of the baseline IR status points to potential role of LTL as a non-specific moderator of metabolic improvement in these patients.

Trial registration: ClinicalTrials.gov NCT01559857.

Conflict of interest statement

JL is a co-founder and consultant to Telomere Diagnostics. The company has no role in this study. NR has been a consultant for the following companies: Shire Pharmaceuticals and Sunovion Pharmaceuticals. She has received research support from the following companies: Magceutics, ADA (American Diabetes Association) and Corcept Pharmaceuticals. None of these companies have a potential role in this study. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Change in HDRS-21 score in the active arm by LTL. HDRS-21, Hamilton Depression Rating Scale 21 Items; LTL, leukocyte telomere length.

References

    1. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569–573.
    1. Blackburn EH. Telomere states and cell fates. Nature 2000; 408: 53–56.
    1. von Zglinicki T, Serra V, Lorenz M, Saretzki G, Lenzen-Grossimlighaus R, Gessner R et al. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? Lab Invest 2000; 80: 1739–1747.
    1. Willeit P, Raschenberger J, Heydon EE, Tsimikas S, Haun M, Mayr A et al. Leucocyte telomere length and risk of type 2 diabetes mellitus: new prospective cohort study and literature-based meta-analysis. PLoS ONE 2014; 12: e112483.
    1. Haycock PC, Heydon EE, Kaptoge S, Butterworth AS, Thompson A, Willeit P. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014; 349: g4227.
    1. Rode L, Nordestgaard BG, Bojesen SE. Peripheral blood leukocyte telomere length and mortality among 64,637 individuals from the general population. J Natl Cancer Inst 2015; 107: djv074.
    1. McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007; 167: 642–648.
    1. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53: 495–499.
    1. Verhoeven JE, Revesz D, Epel ES, Lin J, Wolkowitz OM, Penninx BW. Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol Psychiatry 2014; 19: 895–901.
    1. Cai N, Chang S, Li Y, Li Q, Hu J, Liang J et al. Molecular signatures of major depression. Curr Biol 2015; 25: 1146–1156.
    1. Lindqvist D, Epel ES, Mellon SH, Penninx BW, Révész D, Verhoeven JE et al. Psychiatric disorders and leukocyte telomere length: underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev 2015; 55: 333–364.
    1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 7 million participants. Lancet 2011; 378: 31–40.
    1. Lépine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011; 7: 3.
    1. Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 2013; 36: 480–489.
    1. Rasgon NL, Kenna HA. Insulin resistance in depressive disorders and Alzheimer's disease: revisiting the missing link hypothesis. Neurobiol Aging 2005; 26: 103–107.
    1. McIntyre RS, Kenna HA, Nguyen HT, Law CW, Sultan F, Woldeyohannes HO et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther 2010; 27: 63–80.
    1. Rasgon NL, Carter MS, Elman S, Bauer M, Love M, Korenman SG. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2: 97–102.
    1. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci World J 2010; 10: 321–328.
    1. Watson Lin KT, Wroolie T, Robakis T, Rasgon NL. Adjuvant pioglitazone for unremitted depression. Psychiatr Res 2015. in press.
    1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24–31.
    1. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009; 23: 936–944.
    1. Thase ME. Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies. Dialogues Clin Neurosci 2014; 16: 539–544.
    1. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31–41.
    1. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853–858.
    1. Wolkowitz OM, Epel ES, Reus VI, Mellon SH. Depression gets old fast: do stress and depression accelerate cell aging? Depress Anxiety 2010; 27: 327–338.
    1. Hartmann N, Boehner M, Groenen F, Kalb R. Telomere length of patients with major depression is shortened but independent from therapy and severity of the disease. Depress Anxiety 2010; 27: 1111–1116.
    1. Van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219–242.
    1. Mueller PS, Heninger GR, McDonald RK. Intravenous glucose tolerance test in depression. Arch Gen Psychiatry 1969; 21: 470–477.
    1. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23: 171–175.
    1. First M, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P, 2/2001 revision). American Psychiatric Press, Inc: Washington, DC, USA, 1997.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
    1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
    1. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30, p e47.
    1. Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, Bigos M et al. Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. J Immunol Methods 2010; 352: 71–80.
    1. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis 2007; 195: 83–89.
    1. Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Oliveira C, Justicia A, Griffith JK et al. Abnormal glucose tolerance, white blood cell count, and telomere length in newly diagnosed, antidepressant-naïve patients with depression. Brain Behav Immun 2013; 28: 49–53.
    1. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Dhabhar FS, Su Y et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress. PLoS ONE 62011; e17837.
    1. Hoen PW, de Jonge P, Na BY, Farzaneh-Far R, Epel E, Lin J. Depression and leukocyte telomere length in patients with coronary heart disease: data from the Heart and Soul Study. Psychosom Med 2011; 73: 541–547.
    1. Hoen PW, Rosmalen JG, Schoevers RA, Huzen J, van der Harst P, de Jonge P. Association between anxiety but not depressive disorders and leukocyte telomere length after 2 years of follow-up in a population-based sample. Psychol Med 2013; 4: 689–697.
    1. Huzen J, van der Harst P, de Boer RA, Lesman-Leegte I, Voors AA, van Gilst WH et al. Telomere length and psychological well-being in patients with chronic heart failure. Age Ageing 2010; 39: 223–227.
    1. Schaakxs R, Verhoeven JE, Oude Voshaar RC, Comijs HC, Penninx BW. Leukocyte telomere length and late-life depression. Am J Geriatr Psychiatry 2015; 23: 423–432.
    1. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Reus VI, Rosser R et al. Resting leukocyte telomerase activity is elevated in major depression and predicts treatment response. Mol Psychiatry 2012; 17: 164–172.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅